Redhill Biopharma (NASDAQ:RDHL) Shares Break Below Two Hundred Day Moving Average – Time to Sell?

by · The Markets Daily

Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report)’s share price passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $0.75 and traded as low as $0.46. Redhill Biopharma shares last traded at $0.5073, with a volume of 125,163 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Redhill Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on Redhill Biopharma

Redhill Biopharma Stock Down 7.2%

The business has a 50 day simple moving average of $0.58 and a two-hundred day simple moving average of $0.75.

About Redhill Biopharma

(Get Free Report)

RedHill Biopharma Ltd. was a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases and infectious conditions. Founded in Israel, the company operated internationally, with activities in the United States and other markets through research, regulatory, commercial and licensing relationships.

RedHill’s commercial products included Talicia, a combination therapy approved in the United States for the treatment of Helicobacter pylori infection in adults, and Aemcolo, an extended-release antibiotic approved for certain cases of travelers’ diarrhea caused by noninvasive strains of Escherichia coli.

Featured Articles